Analysts Issue Downgrades on These Healthcare Stocks Last Week

Wall St. Watchdog reveals information about companies for which stock analysts downgraded shares in the Healthcare sector for the week ending November 11th, 2011.

  • Vertex Pharm (NASDAQ:VRTX): RBC Capital Mkts downgraded its rating on this company from Outperform to Sector Perform and changed its price target from $59 to $48 on Nov 7th. The shares recently traded at $30.03, down $3.19, or 9.6% since the analyst’s rating. About the company: Vertex Pharmaceuticals Incorporated discovers, develops, and commercializes novel, small molecule pharmaceuticals for the treatment of diseases for which there are currently limited or no effective treatments. The Company is developing drugs for the treatment of viral diseases, multidrug resistance in cancer, inflammatory and autoimmune diseases, and neurodegenerative diseases. Get the most recent company news and stock data here >>
  • Vertex Pharm (NASDAQ:VRTX): Robert W. Baird downgraded its rating on this company from Outperform to Neutral and changed its price target from $62 to $33 on Nov 8th. The shares recently traded at $30.03, down $0.42, or 1.38% since the analyst’s rating. About the company: Vertex Pharmaceuticals Incorporated discovers, develops, and commercializes novel, small molecule pharmaceuticals for the treatment of diseases for which there are currently limited or no effective treatments. The Company is developing drugs for the treatment of viral diseases, multidrug resistance in cancer, inflammatory and autoimmune diseases, and neurodegenerative diseases. Get the most recent company news and stock data here >>
  • Targacept (NASDAQ:TRGT): Global Hunter Securities downgraded its rating on this company from Buy to Accumulate and changed its price target to $12 on Nov 9th. The shares recently traded at $7.51, down $0.23, or 2.97% since the analyst’s rating. About the company: Targacept Inc. is a a biopharmaceutical company engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting neuronal nicotinic acetylcholine receptors. Get the most recent company news and stock data here >>
  • Savient Pharma (NASDAQ:SVNT): JMP Securities downgraded its rating on this company from Mkt Perform to Mkt Underperform and changed its price target to $1.5 on Nov 10th. The shares recently traded at $2.57, down $0.13, or 4.81% since the analyst’s rating. About the company: Savient Pharmaceuticals Inc. develops, manufactures, and markets human health care products for niche and wider markets. The Company offers pharmaceutical products for a wide range of medical needs such as weight gain, drugs targeting the control of elevated uric acid levels in the blood, and rheumatology. Get the most recent company news and stock data here >>
  • Zimmer Hldgs (NYSE:ZMH): Argus downgraded its rating on this company from Buy to Hold on Nov 11th. About the company: Zimmer Holdings, Inc. designs, develops, manufactures, and markets orthopaedic and dental reconstructive implants, spinal implants, trauma products and related surgical products. The Company also provides other healthcare related services. Zimmer markets its products in the United States and other countries around the world. Get the most recent company news and stock data here >>

(Note: Selected financial data are sourced from Briefing.com via the Wall St. Journal. All data are assumed to be accurate.)

Advantage: Check out our interactive stock charts, fundamentals, Twitter stream, and more >>

Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>

More from The Cheat Sheet